Kairon Labs and Solidus Labs Partner to Redefine Ethical Market Making Under MiCA
12.12.2024 15:00:00 CET | Business Wire | Press release
Kairon Labs, a leading crypto market maker and liquidity provider, has partnered with Solidus Labs, a pioneer in crypto-native compliance and risk management solutions, to strengthen its compliance program and ensure readiness for the European Union's upcoming Markets in Crypto-Assets Regulation (MiCA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212677489/en/
Solidus Labs enters partnership with Kairon Labs (Graphic: Business Wire)
With a proven track record of supporting over 500 digital asset issuers across more than 100 exchanges, Kairon Labs is committed to ethical market-making practices that promote transparency and fairness in the crypto space. By integrating Solidus Labs' trade surveillance technology, Kairon Labs aims to proactively monitor and mitigate market manipulation risks across its operations, reinforcing its dedication to market integrity.
"As regulatory environments become increasingly stringent, it's imperative to uphold the highest standards of compliance," said Jens Willemen, Co-Founder and CEO of Kairon Labs. "Solidus Labs has proven to be the ideal partner for us, thanks to their unmatched expertise in trade surveillance and profound comprehension of the cryptocurrency landscape, especially in the context of the Markets in Crypto-Assets (MiCA) regulation. Their advanced detection algorithms, combined with a holistic compliance platform, align seamlessly with our vision of ensuring a secure trading environment for our clients while maintaining market integrity at every level."
Solidus Labs, a trusted partner for institutions dedicated to crypto integrity, provides Kairon Labs with a robust market integrity toolkit. From real-time anomaly detection to precision-driven behavioral insights, this collaboration will enable thorough monitoring and effective detection of suspicious activities across Kairon’s operations.
"By championing transparency, innovation, and trust, Kairon Labs is shaping the future—one where markets aren’t just made—they’re made better," said Asaf Meir, CEO and Founder of Solidus Labs. "With Solidus, they’re not just prepared for MiCA—they’re setting the gold standard for safe, forward-looking market making. Together, we’re building the foundation for the financial markets of tomorrow."
With MiCA’s sweeping anti-market abuse mandates set to take effect on December 30, 2024, the timing of this collaboration couldn’t be more pivotal. Kairon Labs is demonstrating that in market making, liquidity flows to safety and that market integrity is not just a responsibility—it’s a competitive advantage.
About Kairon Labs:
Kairon Labs is a premier crypto market maker and liquidity provider, offering bespoke algorithmic trading solutions to digital asset issuers. With a focus on ethical market-making practices, Kairon Labs has supported over 500 clients, ensuring successful token launches and sustained market stability. For more information, visit: Kairon Labs
About Solidus Labs
Solidus Labs is the category-definer for crypto-native security and compliance solutions: trade surveillance, transaction monitoring, and staking guard. Solidus Labs leads initiatives like the Crypto Market Integrity Coalition and the DACOM Summit, with a commitment to safe crypto trading across centralized and decentralized markets. For more information, visit: https://soliduslabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212677489/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom